- Immunotherapy and Immune Responses
- vaccines and immunoinformatics approaches
- Viral-associated cancers and disorders
- Advanced biosensing and bioanalysis techniques
- Animal Virus Infections Studies
- Studies on Chitinases and Chitosanases
- RNA modifications and cancer
- RNA Interference and Gene Delivery
- Monoclonal and Polyclonal Antibodies Research
- T-cell and Retrovirus Studies
- Cancer Genomics and Diagnostics
- Circular RNAs in diseases
- Extracellular vesicles in disease
- Galectins and Cancer Biology
- Chromosomal and Genetic Variations
- interferon and immune responses
- Cell Adhesion Molecules Research
- Chemokine receptors and signaling
- Acute Ischemic Stroke Management
- Inflammatory Bowel Disease
- S100 Proteins and Annexins
- Electromagnetic Fields and Biological Effects
- Health and Well-being Studies
- Flavonoids in Medical Research
- Cancer-related molecular mechanisms research
Rockefeller University
2023
Harbin Medical University
2009
Second Affiliated Hospital of Harbin Medical University
2009
Zhejiang Chinese Medical University
1994
Abstract Improved biomarkers are needed for early cancer detection, risk stratification, treatment selection, and monitoring response. Although proteins can be useful blood-based biomarkers, many have limited sensitivity or specificity these applications. Long INterspersed Element-1 (LINE-1) open reading frame 1 protein (ORF1p) is a transposable element overexpressed in carcinomas high-risk precursors during carcinogenesis with negligible expression normal tissues, suggesting ORF1p could...
<p>Calibration curves for “3rd Generation” Simoa assays.</p>
<p>Additional second-generation ORF1p Simoa assay measurements in healthy and cancer patients.</p>
<p>Assay validation for second-generation ORF1p Simoa assays.</p>
<p>Kaplan-Meier Survival Analysis by ORF1p.</p>
<p>Assay validation for second-generation ORF1p Simoa assays.</p>
<p>Screening of multimeric nanobodies for ORF1p detection with Simoa.</p>
<p>Circulating ORF1p levels in patients with IPMN</p>
<p>Circulating ORF1p levels in lung cancer patient cohort</p>
<p>Screening of newly developed monoclonal antibody candidates.</p>
<p>Additional second-generation ORF1p Simoa assay measurements in healthy and cancer patients.</p>
<p>Second round of screening newly developed monoclonal antibody and dimeric nanobody reagent pairs in patient plasma.</p>
<div>Abstract<p>Improved biomarkers are needed for early cancer detection, risk stratification, treatment selection, and monitoring response. Although proteins can be useful blood-based biomarkers, many have limited sensitivity or specificity these applications. Long INterspersed Element-1 (LINE-1) open reading frame 1 protein (ORF1p) is a transposable element overexpressed in carcinomas high-risk precursors during carcinogenesis with negligible expression normal tissues,...
<p>(obtained from Drapkin Lab at the University of Pennsylvania).Circulating CA125 and HE4 levels, as measured by Simoa, in ovarian cancer patient cohort.</p>
<p>Nanobody generation</p>
<p>Calibration curves for “3rd Generation” Simoa assays.</p>
<p>Engineered Nanobody constructs.</p>
<p>First round of screening newly developed monoclonal antibody and dimeric nanobody reagent pairs in patient plasma.</p>
<p>First round of screening newly developed monoclonal antibody and dimeric nanobody reagent pairs in patient plasma.</p>
<p>Genomics analysis of lung cancer patient cohort.</p>
<p>Kaplan-Meier Survival Analysis by ORF1p.</p>
<p>Circulating ORF1p levels in breast cancer patients.</p>
<p>Second round of screening newly developed “3rd generation” assays using dimeric nanobody detectors.</p>
<p>Circulating ORF1p levels in eight stage I ovarian cancer patients</p>
<p>Representative SPR sensorgrams of ORF1 monoclonal antibodies and “2nd Gen.” nanobody multimers.</p>